- Conditions
- Alzheimer's Disease
- Interventions
- Flortaucipir F18, Brain PET scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–41
of 41
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration
- Interventions
- Flortaucipir F18, Brain PET scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 2 more
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Interventions
- Neuraceq, Amyvid, Tauvid, MK-6240, NAV4694, PI-2620
- Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 46 more
- Conditions
- Cognitive Decline, Alzheimer Disease
- Interventions
- [18F]AV-1451
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alzheimer's Disease
- Interventions
- florbetapir F 18, Flortaucipir F18, Brain PET Scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 383 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 20 more
- Conditions
- Cognitive Decline
- Interventions
- Flortaucipir F18, Brain PET scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chronic Traumatic Encephalopathy
- Interventions
- florbetapir F 18, Flortaucipir F18
- Drug
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Boston, Massachusetts
- Conditions
- Alzheimer Disease
- Interventions
- flortaucipir F18, Brain PET Scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
- Interventions
- F-18 AV 1451, C-11 PiB
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Primary Progressive Aphasia With Suspected Alzheimer's Disease
- Interventions
- 18F-AV-1451, PET
- Drug · Device
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 20 Years to 100 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Chronic Traumatic Encephalopathy
- Interventions
- [F18]-T807, [F18]-Florbetapir, MRI/MRS, Genetic Analysis for Genetic Risk Score for Tau.
- Radiation · Device · Genetic
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 40 Years to 69 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer Dementia
- Interventions
- Brain Magnetic Resonance Imaging (MRI), F-18 Florbetapir Positron Emission Tomography (PET) Imaging, F-18 AV-1451 Positron Emission Tomography (PET) Imaging, Neuropsychological Testing
- Diagnostic Test · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 49 Years to 72 Years · Female only
- Enrollment
- 299 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 3 more
- Conditions
- Normal Controls, MCI
- Interventions
- the radiotracer 18F-AV-1451
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Alzheimer Disease
- Interventions
- F 18 T807
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer's Disease
- Interventions
- Flortaucipir F18, PET Scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Los Gatos, California • Newport Beach, California + 23 more
- Conditions
- Cognition Disorders
- Interventions
- 18F-AV-1451
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2023
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • The Villages, Florida + 4 more
- Conditions
- Traumatic Brain Injury
- Interventions
- Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, PET brain imaging, [C-11]6-OH-BTA-1, [F-18]AV-1451
- Diagnostic Test · Drug
- Lead sponsor
- David Okonkwo, MD, PhD
- Other
- Eligibility
- 29 Years to 59 Years · Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania